Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Capital Leases (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Capital Leases over the past 8 years, most recently at $3.2 million for Q2 2024.

  • For Q2 2024, Capital Leases changed 0.03% year-over-year to $3.2 million; the TTM value through May 2024 reached $3.2 million, changed 0.03%, while the annual FY2024 figure was $3.2 million, 0.03% changed from the prior year.
  • Capital Leases for Q2 2024 was $3.2 million at Lifecore Biomedical, Inc. \De\, roughly flat from $3.2 million in the prior quarter.
  • Over five years, Capital Leases peaked at $26.4 million in Q2 2020 and troughed at $12000.0 in Q2 2022.
  • A 4-year average of $7.3 million and a median of $3.2 million in 2024 define the central range for Capital Leases.
  • Biggest five-year swings in Capital Leases: fell 2.67% in 2020 and later surged 26683.33% in 2023.
  • Year by year, Capital Leases stood at $26.4 million in 2020, then plummeted by 99.95% to $12000.0 in 2022, then surged by 26683.33% to $3.2 million in 2023, then increased by 0.03% to $3.2 million in 2024.
  • Business Quant data shows Capital Leases for LFCR at $3.2 million in Q2 2024, $3.2 million in Q2 2023, and $12000.0 in Q2 2022.